2018年度

原著論文

1. Mutational activation of the EGFR down-regulates MHC class I expression via the ERK in non-small cell lung cancer. Watanabe S, Hayashi H, Haratani K, Shimizu S, Tanizaki J, Sakai K, Kawakami H, Yonesaka K, Tsurutani J, Togashi Y, Nishio K, Ito A, Nakagawa K. Cancer Sci. 2018 Nov 3. doi: 10.1111/cas.13860. [Epub ahead of print]

2. aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer. Fujita Y, Taguri M, Yamazaki K, Tsurutani J, Sakai K, Tsushima T, Nagase M, Tamagawa H, Ueda S, Tamura T, Tsuji Y, Murata K, Taira K, Denda T, Moriwaki T, Funai S, Nakajima TE, Muro K, Tsuji A, Yoshida M, Suyama K, Kurimoto T, Sugimoto N, Baba E, Seki N, Sato M, Shimura T, Boku N, Hyodo I, Yamanaka T, Nishio K.

3. Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study.Tsurutani J, Sakata Y, Matsuoka T.Breast Cancer. 2018 Oct 15. doi: 10.1007/s12282-018-0919-8. [Epub ahead of print]

4. KRAS and EGFR amplifications mediate resistance to rociletinib and osimertinib in acquired afatinib-resistant NSCLC harboring exon 19 deletion/T790M in EGFR.　Nakatani K, Yamaoka T, Ohba M, Fujita KI, Arata S, Kusumoto S, Taki-Takemoto I, Kamei D, Iwai S, Tsurutani J, Ohmori T.Mol Cancer Ther. 2018 Oct 15. pii: molcanther.0591.2018. doi: 10.1158/1535-7163.MCT-18-0591. [Epub ahead of print]

総説

●作成中

学会発表

●作成中

著書

●作成中

講演

●作成中